Suspendu

Assessing Safety of OvaPrime Procedure in Women with Primary Ovarian Insufficiency or Poor Ovarian Response

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

OvaPrime Treatment

Autre
Qui peut participer

Maladies génito-urinaires+7

+ Maladies Génitales

+ Maladies Annexielles

De 21 à 45 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Étude thérapeutique

Interventionnel
Date de début : octobre 2016
Voir le détail du protocole

Résumé

Sponsor principalOvaScience, Inc.
Dernière mise à jour : 27 janvier 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 octobre 2016

Date à laquelle le premier participant a commencé l'étude.

This research study focuses on evaluating the safety of the OvaPrime procedure in women diagnosed with primary ovarian insufficiency (POI) or poor ovarian response (POR). The primary goal is to understand the safety aspects of this procedure in these women. POI is a condition where the ovaries stop functioning normally before the age of 40, while POR refers to a lesser than expected response to fertility medication. This study is important as it could potentially offer a new treatment option for these conditions, addressing unmet needs in women's reproductive health. A maximum of 95 women will participate in this study, with at least 30 having POI and 50 with POR. Each participant will have one ovary exposed to the EggPC cells (part of the OvaPrime procedure), while the other ovary will be exposed to the EggPC vehicle, acting as a control. This allows each participant to serve as their own control in the study. The results between the treatment and control ovary will be compared for relevant endpoints such as antral follicle counts. The study will last approximately 6 years, including enrollment, treatment, and a 5-year follow-up. The safety of the procedure will be evaluated by monitoring adverse events and serious adverse events in all subjects, regardless of pregnancy. For those who become pregnant, they will be followed through pregnancy and 1-year post-partum, with the safety of the offspring monitored up to one year post-delivery in the main study, and up to 5 years in a long-term follow-up study.

Titre officielSingle Center, Prospective Controlled Pilot Study of the OvaPrime Procedure
Sponsor principalOvaScience, Inc.
Dernière mise à jour : 27 janvier 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

81 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Traitement

Cette étude teste un ou plusieurs traitements pour évaluer leur efficacité contre une maladie ou un problème de santé spécifique. L'objectif est de voir si un nouveau médicament ou une thérapie fonctionne mieux, ou provoque moins d'effets secondaires que les options existantes.



Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

De 21 à 45 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Maladies génito-urinairesMaladies GénitalesMaladies AnnexiellesMaladies du système endocrinienMaladies urogénitales féminines et complications de la grossesseMaladies génitales fémininesTroubles GonadiquesMaladies des ovairesInsuffisance Ovarienne PrimaireMaladies urogénitales féminines

Critères

Inclusion Criteria: 1. Subjects who are diagnosed with EITHER POI or POR as defined below: * POI subjects who are: * \< 40 years of age * have non-detectable AMH * FSH \>15.0 mIU/ml and/or symptoms of menopause * POR (based on European Society of Human Reproduction and Embryology (ESHRE) guidelines must have two of the following: * 40 years of age * A previous IVF cycle with \< 3 oocytes with a standard of care controlled ovarian hyperstimulation protocol * An abnormal ovarian reserve test defined as: 1. AFC \< 5 - 7 follicles or 2. AMH \< 0.5 - 1.1 ng/ml or 3. Highest ever baseline FSH \> 15.0 ml U/ml 2. Subject must have both ovaries. 3. Subject agrees to participate in main study follow up as well as Long Term Follow-up (LTFU) sub-study 4. Subject's male partner or sperm donor source must meet the following requirements: * Semen must be an ejaculate (not surgically derived, epididymal, testicular, electro- ejaculated sperm), collected by ejaculation. * Male partner's testes must not have been exposed to chemotherapy. * Semen must have some morphologically normal spermatozoa according to the World Health Organization (see table below) and adequate concentration with some motile spermatozoa for insemination of all oocytes by intra-cytoplasmic sperm injection (ICSI). WHO Semen variable 2010 Volume (mL) 1.5 Concentration (106 mL-1) 15 Total sperm number (106/ejaculate) 39 Motility (% motile) 40 (a + b + c) Forward progression 32 (a + b) Morphology (% normal) 4 Viability/vitality (% live) 58 White blood cells (106 mL-1) \< 1.0 5. Partner must also agree to all research study requirements including follow up (including main study as well as LTFU sub-study) of offspring and sign consent form (not applicable in the case of a woman using sperm donation). Exclusion Criteria: 1. Subject with a diagnosis of POI who is ≥ 40 years of age or \< 21 years of age at the time of the OvaPrime procedure 2. Subject with onset of POI \< 18 years of age 3. Subject with a diagnosis of POR who is \> 45 years of age at the time of the OvaPrime procedure 4. Subject has had any prior surgery/medical condition that would prevent direct access to the ovaries (e.g., pelvic adhesions, tubo- ovarian adhesions location/displacement of the ovary(ies) or high body mass index (BMI)). 5. Subject has severe (stage IV) endometriosis or presence of an endometrioma 6. Subject has a unilateral or bilateral untreated hydrosalpinx 7. Subject has participated in the active phase of another investigational trial within the previous 30 days 8. Subject has a history of prior chemotherapy or radiation therapy to the pelvis 9. Subjects and/or partner (supplying sperm) with known karyotypic abnormalities 10. Subjects with POI who have FMR1 premutations or an FMRI mutation 11\. Subjects who are positive for the hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

Un seul groupe d'intervention est désigné dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Groupe I

The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

Suspendu

TRIO

Toronto, CanadaOuvrir TRIO dans Google Maps
Suspendu1 Centres d'Étude